Ventyx Biosciences — Investor Presentation (June 2022)
37 slides from Ventyx Biosciences's investor presentation, Jun 29, 2022
Slide 1: Corporate Presentation June 29, 2022
CORPORATE PRESENTATION June 29, 2022 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are
Slide 3: Introduction & Pipeline
VTX958 | TYK2 Inhibitor | Phase 1 VTX002 | S1P1R Modulator | Phase 2 VTX2735 | Peripheral NLRP3 Inhibitor | Phase 1 Complete VTX3232 | CNS-penetrant NLRP3 Inhibitor | Pre-clinical Summary | Milestones & highlights INTRODUCTION & PIPELINE
Slide 4: Our Leadership Team
BOARD OF DIRECTORS Sheila Gujrathi, MD Executive Chair, Ventyx Raju Mohan, PhD Chief Executive Officer, Founder Martin Auster, MD Chief Financial Officer Chris Krueger, JD Chief Business Officer John Nuss, PhD Chief Scientific Officer William Sandborn, MD PRESIDENT, Chief Medical Officer MANAGEMENT
Slide 5: Underpinned by Strong Drug Discovery and Development Capabilities
Our experienced team and our internal R&D engine continue to generate candidates with potential to address diseases with high unmet need Our internally-discovered small molecule drugs allow us to own 100% commercial rights to our entire portfolio with long patent lives for all product candidates Wit
Slide 6: Broad Pipeline of Candidates With Multiple Near-Term Catalysts
TARGET PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT ANTICIPATED MILESTONES TYK2 VTX958 Report topline Phase 1 data Q3 2022 Initiate Phase 2 POC trials H2 2022 S1P1R VTX002 Report topline Phase 2 data 2023 NLRP3 Peripheral VTX2735 Initiate POC trial in CAPS Q4 2022 NLRP3 CNS-penetrant VTX3232 Fil
Slide 7: Pipeline Targeting Large Well-Established Markets
Indication* PATIENTS in the U.S. Global drug revenue* (2020) Target Population Psoriasis Dermatology ~8M ~$20B 25-30% moderate-to-severe Crohn’s disease IBD ~700K ~$13B 30-40% moderate-to-severe Ulcerative colitis IBD ~1M ~$7B 30-40% moderate-to-severe Psoriatic arthritis Rheumatology ~1M ~$4B 40-60
Slide 8: Orally bioavailable selective allosteric inhibitor of TYK2
ORALLY BIOAVAILABLE selective allosteric inhibitor of TYK2
Slide 9: VTX958 Program Summary
VTX958 Program Summary *Includes approved drugs Stelara™ (JNJ), Tremfya® (JNJ), Skyrizi™(ABBV), Ilumya™ (Sun Pharma) and others in late-stage development (mirikizumab (LLY), brazikumab (AZN) **Deucravacitinib efficacy reported on 16-week primary endpoint of PASI-75 (75% reduction of psoriasis affect
Slide 10: VTX958 Binds Selectively to the TYK2 JH2 Domain
Inactive Active IL-12, IL-23, IFNα Inhibited VTX958 JH2 JH1 TYK2 Features of VTX958 JH2 Allosteric Inhibition Selectivity for TYK2 JH2 vs. JAK1 JH2 domain (>4,000 X) No binding to JAK2/3 JH2 domains No binding to TYK2 kinase JH1 and No kinase enzyme inhibition of any JAK family member FERM/SH2 Recep
Slide 11: VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain
VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain Source: Ventyx internal data Deucravacitinib VTX958 TYK2-JH2 Binding Kd 0.009 nM 0.058 nM JAK1-JH2 Binding Kd 0.43 nM 240 nM Selectivity (fold) 48 >4,000 JAK1 JAK3 IL-2, IL-4 IL-13, IL-15 JAK1 JAK2 IFNγ IL-10,IL-22 IL-6 JAK1 other JAK JA
Slide 12: VTX958 Selectively Targets IL-12, IL-23 and IFNα
VTX958 Selectively Targets IL-12, IL-23 and IFNα Source: Ventyx internal data; conducted in peripheral blood mononuclear cells (PBMC) Pleiotropic Cytokines with Protective Functions Drug IL-22 IC50 (nM) IL-10 IC50 (nM) IFNγ IC50 (nM) IL-4 IC50 (nM) IL-6 IC50 (nM) VTX958 >10,000 >10,000 >10,000 >10,0
Slide 13: VTX958 Phase 1 SAD Results Support Clinical Advancement
VTX958 Phase 1 SAD Results Support Clinical Advancement NOTE: SAD = single ascending dose; AE= adverse event; dose-related exposures are observed at all doses Well-tolerated across all cohorts; all AEs observed were mild and not dose- or time-of-dose dependent No dose-saturation observed; PK and abs
Slide 14: Targeting a Best-in-Class Exposure Profile With VTX958
Targeting a Best-in-Class Exposure Profile With VTX958 Note: Exposure curves are adapted from corporate presentations and publications, as noted Allosteric TYK2 Inhibitors – Target Coverage Plasma Concentration (nM) Time (hours) Derived Concentrations (ng/mL) Time (hours) Deucravacitinib (BMS) 6mg Q
Slide 15: VTX958 Profile Expected to Drive Clinical Differentiation
VTX958 Profile Expected to Drive Clinical Differentiation Note: Solid area represents pbo-adjusted response rate; dashed area indicates total observed response rate; primary endpoint cut-off ranges from Week 10 to Week 16 Sources: Company reports and FDA labels for approved anti-IL-17 and anti-IL-23
Slide 16: Unlocking the Opportunity in Crohn's Disease
Unlocking the Opportunity in Crohn’s Disease *Source: FDA labels for approved drugs/indications; Skyrizi represents dose submitted for FDA approval. Note: maintenance dose unless otherwise specified. **Represents Phase 2 doses; specific Phase 3 doses not disclosed. Several-fold Higher Doses Required
Slide 17: VTX958 Clinical Development Plan
VTX958 Clinical Development Plan NOTE: SAD = single ascending dose; MAD = multiple ascending dose; PoC = proof-of-concept Phase 1 SAD All 7 cohorts completed Safety and exposure data allow exploration of high exposure multiples in MAD trial Phase 1 MAD Explore safety and exposure data on repeat dosi
Slide 18: Peripherally restricted S1P1R modulator for ulcerative colitis
PERIPHERALLY RESTRICTED S1P1R MODULATOR with potential for treatment of ulcerative colitis
Slide 19: VTX002 Program Summary
Phase 2 S1P1R Modulator for Ulcerative Colitis VTX002 Program Summary Ulcerative colitis is lead indication totaling up to $7B in worldwide revenue Selective S1P1R modulator Differentiated on key parameters Demonstrated pharmacodynamic activity in Phase 1 trial Pursuing clinical development plan in
Slide 20: VTX002 Differentiates on Multiple Key Parameters
Sustained lymphocyte reduction up to 65% across multiple doses in MAD trial VTX002 Differentiates on Multiple Key Parameters vs. Competitors Notes: SAE=significant adverse event; MAD=multiple ascending dose No SAEs, elevated LFTs, abnormal PFTs or macular edema No long-acting circulating metabolites
Slide 21: VTX002 Differentiates on Multiple Key Parameters vs. Competitors
VTX002 Differentiates on Multiple Key Parameters vs. Competitors Differentiating Parameter Ozanimod Etrasimod VTX002 Receptor Selectivity S1P 1,5 S1P 1,4,5 S1P 1,5 Lymphocyte Suppression in Healthy Volunteers 1 mg, ~60% 2 mg, 69% 40 mg, ~65% Lymphocyte Suppression in UC Patients 1 mg, 49% 2 mg, 40%
Slide 22: Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction
Pharmacodynamics Pharmacokinetics Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction Source: NEJM (2016), Gastroenterology (2020) *Ph2 UC ALC reduction from baseline: 1mg ozanimod (49%), 2mg etrasimod (40%) T1/2 of ~20 hours Dose-proportionate exposure after single and multiple do
Slide 23: Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis
Phase 2 Induction Trial in Moderate-to-Severe Ulcerative Colitis Baseline Week 13* Week 52 12-Week Treatment Period Patients with LOR Placebo VTX002, 60 mg VTX002, 30 mg VTX002, 60 mg VTX002, 30 mg Placebo Week 13 * includes 7-day titration Screening Period 39-Week LTE Treatment Period 13-Week Treat
Slide 24: Addressable UC Patient Population in US
Addressable UC Patient Population in US VTX002 TARGET POPULATION ~1M UC PATIENTS 300K+ moderate-to-severe UC patients ~100K biologic-treated patients >50K Existing agents leave room for new treatments Novel oral agents may expand penetrance of treated moderate-to-severe UC population beyond current
Slide 25: Selective NLRP3 Inflammasome Inhibitors for systemic and CNS indications
SELECTIVE NLRP3 INFLAMMASOME INHIBITORS for systemic and CNS indications
Slide 26: Rationale for Targeting the NLRP3 Inflammasome
Rationale for Targeting the NLRP3 Inflammasome NLRP3 = NOD-like receptor family, pyrin domain-containing protein 3; IL-1β = interleukin-1β NLRP3 Inflammasome Inhibitors Target IL-1β, a Key Driver of Inflammatory Disease The NLRP3 inflammasome can become overactive in the presence of persistent tissu
Slide 27: NLRP3 Inhibitor Program Summary
NLRP3 Inhibitor Program Summary Peripheral NLRP3 Inhibitor: VTX2735 CNS NLRP3 Inhibitor: VTX3232 Selective NLRP3 inhibitor Well tolerated in GLP safety and tox assessment Phase 1 completed with attractive safety/tolerability profile and evidence of pharmacodynamic activity Phase 2 trial in CAPS plan
Slide 28: VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor
VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor MCC950 is an NLRP3 inhibitor and a control compound used in in vitro and in vivo studies IL-1β IC50 (nM) On Target human monocytes 2 human whole blood 75 Off Target AIM2 >10000 NLRC4 >10000 NF-kb >10000 Non-Human Primate PK Mouse Pharmacod
Slide 29: Summary of VTX2735 Phase 1 Results
Summary of VTX2735 Phase 1 Results Excellent Safety and Pharmacodynamic Activity Concentration-Dependent Suppression of IL-1β Ex Vivo Safety All AEs considered mild No LFT abnormalities No dose-related increase in frequency of AEs observed PK Dose-proportionate increases in exposure (Cmax and AUC) T
Slide 30: VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations
IC50 in Blood Monocyte Assay (nM) VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations *Source: UCSD (Dr. Hal Hoffman’s lab); CAPS=Cryopyrin-Associated Periodic Syndromes VTX2735 blood assay data from CAPS patients suggest inhibitory activity across several mutations: FCAS, MWS and NOMID subs
Slide 31: CNS-Penetrant NLRP3 Inhibitor VTX3232
CNS-Penetrant NLRP3 Inhibitor VTX3232 In Vitro Potency & Selectivity IL-1β IC50 (nM) NLRP3 huWB 13 AIM2 BMDM >10000 NLRC4 BMDM >10000 NF-kb BMDM >10000 Rat PK (PO, 5mg/kg) T½ = 4.4 h; Oral Bioavailability = 75% Dog PK (PO, 5mg/kg) T½ = 8 h; Oral Bioavailability = 100% WB IC50 CSF Conc. ~20 x WB IC50
Slide 32: NLRP3 Program Clinical Development Plan
NLRP3 Program Clinical Development Plan COMPLETE IND-enabling Studies September 2021 IND approved Q4 2021 Initiate Phase 2 CAPS Further indications TBD Q4 2022 VTX2735 PERIPHERALLY-RESTRICTED VTX3232 CNS-PENETRANT INHIBITOR IND-Enabling Studies Potential indications include Parkinson’s, Alzheimer’s,
Slide 33: Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases
Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases NLRP3 Alzheimer’s Disease Parkinson’s Disease ALS Multiple Sclerosis Neuroinflammatory Diseases CNS-directed NLRP3 inhibitors are designed to treat a range of neuro-degenerative disorders, such as Alzheimer’s and
Slide 34: Projected Pipeline Catalysts and Summary
Projected Pipeline Catalysts and Summary
Slide 35: Projected Catalysts Over Next Months
Projected Catalysts Over Next 24 Months *Following completion of our Phase 1 trial, we intend to initiate Phase 2 trials in psoriasis, psoriatic arthritis, Crohn’s disease and potentially other indications ** Following regulatory acceptance of planned Q4 2022 IND filing, we intend to initiate and co
Slide 36: Investment Highlights
Investment Highlights Efficient & Productive Immunology Platform Internal R&D engine designed to generate candidates to address autoimmune and inflammatory diseases with high unmet need 100% commercial rights to entire portfolio; long patent life for all product candidates Potentially Differentiated
Slide 37: Contact us for additional information
Contact us for additional information: [email protected] VENTYX BIOSCIENCES, INC. 662 ENCINITAS BOULEVARD, SUITE 250 ENCINITAS, CA 92024
Ventyx Biosciences — Investor Presentation (June 2022) on 6ix